Abstract
Current treatments for inflammatory bowel diseases (IBDs) are suboptimal. Approximately 30% of patients are primary nonresponders to initial treatment, and approximately 50% of patients become secondary nonresponders to drugs, including the recently approved or to be approved therapies.1 A review of the rates of clinical remission across the various tumor necrosis factor-α (TNF-α) inhibitors demonstrates a ceiling effect ranging from 18% to 48% at the end of the induction phase and from 25.6% to 59% at weeks 20 to 30, even among initial responders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
